Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Co-emergence and Collapse: The Mesoscopic Approach for Conceptualizing and Investigating the Functional Integration of Organisms.

Bizzarri M, Giuliani A, Pensotti A, Ratti E, Bertolaso M.

Front Physiol. 2019 Jul 26;10:924. doi: 10.3389/fphys.2019.00924. eCollection 2019.

2.

Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies.

Carboni L, McCarthy DJ, Delafont B, Filosi M, Ivanchenko E, Ratti E, Learned SM, Alexander R, Domenici E.

Transl Psychiatry. 2019 Aug 2;9(1):182. doi: 10.1038/s41398-019-0521-7.

3.

Strategies to Address Challenges in Neuroscience Drug Discovery and Development.

O'Donnell P, Rosen L, Alexander R, Murthy V, Davies CH, Ratti E.

Int J Neuropsychopharmacol. 2019 Jul 1;22(7):445-448. doi: 10.1093/ijnp/pyz027.

4.

The Italian autism network (ITAN): a resource for molecular genetics and biomarker investigations.

Muglia P, Filosi M, Da Ros L, Kam-Thong T, Nardocci F, Trabetti E, Ratti E, Rizzini P, Zuddas A, Bernardina BD, Domenici E; Italian Autism Network.

BMC Psychiatry. 2018 Nov 21;18(1):369. doi: 10.1186/s12888-018-1937-y.

5.

Alpha6-Containing Nicotinic Acetylcholine Receptors Mediate Nicotine-Induced Structural Plasticity in Mouse and Human iPSC-Derived Dopaminergic Neurons.

Collo G, Cavalleri L, Zoli M, Maskos U, Ratti E, Merlo Pich E.

Front Pharmacol. 2018 Jun 1;9:572. doi: 10.3389/fphar.2018.00572. eCollection 2018.

6.

Conceptual Challenges in the Theoretical Foundations of Systems Biology.

Bertolaso M, Ratti E.

Methods Mol Biol. 2018;1702:1-13. doi: 10.1007/978-1-4939-7456-6_1.

PMID:
29119498
7.

Comparison of Medical and Consumer Wireless EEG Systems for Use in Clinical Trials.

Ratti E, Waninger S, Berka C, Ruffini G, Verma A.

Front Hum Neurosci. 2017 Aug 3;11:398. doi: 10.3389/fnhum.2017.00398. eCollection 2017.

8.

Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis.

Atassi N, Xu M, Triantafyllou C, Keil B, Lawson R, Cernasov P, Ratti E, Long CJ, Paganoni S, Murphy A, Salibi N, Seethamraju R, Rosen B, Ratai EM.

PLoS One. 2017 May 12;12(5):e0177680. doi: 10.1371/journal.pone.0177680. eCollection 2017.

9.

Defining SOD1 ALS natural history to guide therapeutic clinical trial design.

Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, Ratti E, Atassi N, Boylan KB, Glass JD, Maragakis NJ, Caress JB, McCluskey LF, Appel SH, Wymer JP, Gibson S, Zinman L, Mozaffar T, Callaghan B, McVey AL, Jockel-Balsarotti J, Allred P, Fisher ER, Lopate G, Pestronk A, Cudkowicz ME, Miller TM.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):99-105. doi: 10.1136/jnnp-2016-313521. Epub 2016 Jun 3.

10.

Why genes are like lemons.

Boem F, Ratti E, Andreoletti M, Boniolo G.

Stud Hist Philos Biol Biomed Sci. 2016 Jun;57:88-95. doi: 10.1016/j.shpsc.2016.04.005. Epub 2016 May 4.

PMID:
27155220
11.

Preclinical Rodent Toxicity Studies for Long Term Use of Ceftriaxone.

Ratti E, Berry JD, Greenblatt DJ, Loci L, Ellrodt AS, Shefner JM, Cudkowicz ME.

Toxicol Rep. 2015;2:1396-1403.

12.

Neurokinin-1 receptor antagonist orvepitant is an effective inhibitor of itch-associated response in a Mongolian gerbil model of scratching behaviour.

Trower MK, Fisher A, Upton N, Ratti E.

Exp Dermatol. 2014 Nov;23(11):858-60. doi: 10.1111/exd.12528.

PMID:
25078633
13.

Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.

Inamdar A, Merlo-Pich E, Gee M, Makumi C, Mistry P, Robertson J, Steinberg E, Zamuner S, Learned S, Alexander R, Ratti E.

J Psychopharmacol. 2014 Jun;28(6):570-81. doi: 10.1177/0269881114529377. Epub 2014 Apr 2.

PMID:
24699061
14.

NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes.

An O, Pendino V, D'Antonio M, Ratti E, Gentilini M, Ciccarelli FD.

Database (Oxford). 2014 Mar 7;2014:bau015. doi: 10.1093/database/bau015. Print 2014.

15.

Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET.

Ridler K, Gunn RN, Searle GE, Barletta J, Passchier J, Dixson L, Hallett WA, Ashworth S, Gray FA, Burgess C, Poggesi I, Bullman JN, Ratti E, Laruelle MA, Rabiner EA.

J Psychopharmacol. 2014 Mar;28(3):244-53. doi: 10.1177/0269881113517953. Epub 2014 Jan 15.

PMID:
24429221
16.

Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.

Ratti E, Carpenter DJ, Zamuner S, Fernandes S, Squassante L, Danker-Hopfe H, Archer G, Robertson J, Alexander R, Trist DG, Merlo-Pich E.

Sleep. 2013 Dec 1;36(12):1823-30. doi: 10.5665/sleep.3208.

17.

Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists.

Trist DG, Ratti E, Bye A.

J Recept Signal Transduct Res. 2013 Dec;33(6):333-7. doi: 10.3109/10799893.2013.843194. Epub 2013 Oct 9. Review.

PMID:
24106886
18.

Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.

Di Fabio R, Alvaro G, Braggio S, Carletti R, Gerrard PA, Griffante C, Marchioro C, Pozzan A, Melotto S, Poffe A, Piccoli L, Ratti E, Tranquillini E, Trower M, Spada S, Corsi M.

Bioorg Med Chem. 2013 Nov 1;21(21):6264-73. doi: 10.1016/j.bmc.2013.09.001. Epub 2013 Sep 11.

PMID:
24075145
19.

Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies.

Ratti E, Bettica P, Alexander R, Archer G, Carpenter D, Evoniuk G, Gomeni R, Lawson E, Lopez M, Millns H, Rabiner EA, Trist D, Trower M, Zamuner S, Krishnan R, Fava M.

J Psychopharmacol. 2013 May;27(5):424-34. doi: 10.1177/0269881113480990. Epub 2013 Mar 28.

PMID:
23539641
20.

The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia.

Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E.

Sleep. 2012 Aug 1;35(8):1097-104. doi: 10.5665/sleep.1996.

21.

The association of rs4307059 and rs35678 markers with autism spectrum disorders is replicated in Italian families.

Prandini P, Pasquali A, Malerba G, Marostica A, Zusi C, Xumerle L, Muglia P, Da Ros L, Ratti E, Trabetti E, Pignatti PF; Italian Autism Network (ITAN).

Psychiatr Genet. 2012 Aug;22(4):177-81. doi: 10.1097/YPG.0b013e32835185c9.

PMID:
22739633
22.

Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials.

Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, Ratti E.

J Psychopharmacol. 2012 May;26(5):653-62. doi: 10.1177/0269881111424931. Epub 2011 Nov 2.

PMID:
22048884
23.

Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder.

Ratti E, Bellew K, Bettica P, Bryson H, Zamuner S, Archer G, Squassante L, Bye A, Trist D, Krishnan KR, Fernandes S.

J Clin Psychopharmacol. 2011 Dec;31(6):727-33. doi: 10.1097/JCP.0b013e31823608ca. Erratum in: J Clin Psychopharmacol. 2012 Apr;32(2):185.

PMID:
22020354
24.

A pharmacokinetic PET study of NK₁ receptor occupancy.

Zamuner S, Rabiner EA, Fernandes SA, Bani M, Gunn RN, Gomeni R, Ratti E, Cunningham VJ.

Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):226-35. doi: 10.1007/s00259-011-1954-2. Epub 2011 Oct 13.

PMID:
21993526
25.

Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.

Di Fabio R, Pellacani A, Faedo S, Roth A, Piccoli L, Gerrard P, Porter RA, Johnson CN, Thewlis K, Donati D, Stasi L, Spada S, Stemp G, Nash D, Branch C, Kindon L, Massagrande M, Poffe A, Braggio S, Chiarparin E, Marchioro C, Ratti E, Corsi M.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5562-7. doi: 10.1016/j.bmcl.2011.06.086. Epub 2011 Jun 30.

PMID:
21831639
26.

Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist.

Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, Gomeni R, Alexander R.

J Psychopharmacol. 2012 Aug;26(8):1058-70. doi: 10.1177/0269881111408954. Epub 2011 Jul 5.

PMID:
21730017
27.

[Methodological and operational notes for the assessment and management of the risk of work-related stress].

De Ambrogi F, Ratti EC.

G Ital Med Lav Ergon. 2011 Jul-Sep;33(3 Suppl B):B21-7. Review. Italian.

PMID:
23326946
28.

Synthesis and structure-activity relationship of new 1,5-dialkyl-1,5-benzodiazepines as cholecystokinin-2 receptor antagonists.

Roberts K, Ursini A, Barnaby R, Cassarà PG, Corsi M, Curotto G, Donati D, Feriani A, Finizia G, Marchioro C, Niccolai D, Oliosi B, Polinelli S, Ratti E, Reggiani A, Tedesco G, Tranquillini ME, Trist DG, van Amsterdam FT.

Bioorg Med Chem. 2011 Jul 15;19(14):4257-73. doi: 10.1016/j.bmc.2011.05.057. Epub 2011 Jun 6.

PMID:
21689940
29.

Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.

Di Fabio R, Alvaro G, Griffante C, Pizzi DA, Donati D, Mattioli M, Cimarosti Z, Guercio G, Marchioro C, Provera S, Zonzini L, Montanari D, Melotto S, Gerrard PA, Trist DG, Ratti E, Corsi M.

J Med Chem. 2011 Feb 24;54(4):1071-9. doi: 10.1021/jm1013264. Epub 2011 Jan 13.

PMID:
21229983
30.

A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial.

Mathew SJ, Vythilingam M, Murrough JW, Zarate CA Jr, Feder A, Luckenbaugh DA, Kinkead B, Parides MK, Trist DG, Bani MS, Bettica PU, Ratti EM, Charney DS.

Eur Neuropsychopharmacol. 2011 Mar;21(3):221-9. doi: 10.1016/j.euroneuro.2010.11.012. Epub 2010 Dec 30.

31.

Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates.

Braggio S, Montanari D, Rossi T, Ratti E.

Expert Opin Drug Discov. 2010 Jul;5(7):609-18. doi: 10.1517/17460441.2010.490553. Epub 2010 May 20.

PMID:
22823203
32.

6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.

Micheli F, Cavanni P, Andreotti D, Arban R, Benedetti R, Bertani B, Bettati M, Bettelini L, Bonanomi G, Braggio S, Carletti R, Checchia A, Corsi M, Fazzolari E, Fontana S, Marchioro C, Merlo-Pich E, Negri M, Oliosi B, Ratti E, Read KD, Roscic M, Sartori I, Spada S, Tedesco G, Tarsi L, Terreni S, Visentini F, Zocchi A, Zonzini L, Di Fabio R.

J Med Chem. 2010 Jul 8;53(13):4989-5001. doi: 10.1021/jm100481d.

PMID:
20527970
33.

1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.

Micheli F, Arista L, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, Damiani F, Di-Fabio R, Fontana S, Gentile G, Griffante C, Hamprecht D, Marchioro C, Mugnaini M, Piner J, Ratti E, Tedesco G, Tarsi L, Terreni S, Worby A, Ashby CR Jr, Heidbreder C.

J Med Chem. 2010 Jan 14;53(1):374-91. doi: 10.1021/jm901319p.

PMID:
19891474
34.

Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.

Heldt SA, Davis M, Ratti E, Corsi M, Trist D, Ressler KJ.

Behav Pharmacol. 2009 Oct;20(7):584-95. doi: 10.1097/FBP.0b013e32832ec594.

35.

Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.

Di Fabio R, Griffante C, Alvaro G, Pentassuglia G, Pizzi DA, Donati D, Rossi T, Guercio G, Mattioli M, Cimarosti Z, Marchioro C, Provera S, Zonzini L, Montanari D, Melotto S, Gerrard PA, Trist DG, Ratti E, Corsi M.

J Med Chem. 2009 May 28;52(10):3238-47. doi: 10.1021/jm900023b.

PMID:
19388677
36.

Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responses.

Walker D, Yang Y, Ratti E, Corsi M, Trist D, Davis M.

Neuropsychopharmacology. 2009 May;34(6):1533-42. doi: 10.1038/npp.2008.210. Epub 2008 Dec 10.

37.

Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.

Di Fabio R, St-Denis Y, Sabbatini FM, Andreotti D, Arban R, Bernasconi G, Braggio S, Blaney FE, Capelli AM, Castiglioni E, Di Modugno E, Donati D, Fazzolari E, Ratti E, Feriani A, Contini S, Gentile G, Ghirlanda D, Provera S, Marchioro C, Roberts KL, Mingardi A, Mattioli M, Nalin A, Pavone F, Spada S, Trist DG, Worby A.

J Med Chem. 2008 Dec 11;51(23):7370-9. doi: 10.1021/jm800744m.

PMID:
18989952
38.

Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.

Di Fabio R, Arban R, Bernasconi G, Braggio S, Blaney FE, Capelli AM, Castiglioni E, Donati D, Fazzolari E, Ratti E, Feriani A, Contini S, Gentile G, Ghirlanda D, Sabbatini FM, Andreotti D, Spada S, Marchioro C, Worby A, St-Denis Y.

J Med Chem. 2008 Nov 27;51(22):7273-86. doi: 10.1021/jm800743q.

PMID:
18975927
39.

A novel ketolide class: Synthesis and antibacterial activity of a lead compound.

Andreotti D, Bientinesi I, Biondi S, Donati D, Erbetti I, Lociuro S, Marchioro C, Pozzan A, Ratti E, Terreni S.

Bioorg Med Chem Lett. 2007 Sep 15;17(18):5265-9. Epub 2007 Feb 9.

PMID:
17681467
40.

Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.

Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM, Kalin NH, Ratti E, Nemeroff CB, Miller AH.

Biol Psychiatry. 2007 Dec 1;62(11):1324-33. Epub 2007 Aug 2.

41.

Chiral tetrahydroquinoline derivatives as potent anti-hyperalgesic agents in animal models of sustained inflammation and chronic neuropathic pain.

Di Fabio R, Alvaro G, Bertani B, Donati D, Pizzi DM, Gentile G, Pentassuglia G, Giacobbe S, Spada S, Ratti E, Corsi M, Quartaroli M, Barnaby RJ, Vitulli G.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1176-80. Epub 2006 Dec 12.

PMID:
17218099
42.

Studies towards the identification of a new generation of atypical antipsychotic agents.

Garzya V, Forbes IT, Gribble AD, Hadley MS, Lightfoot AP, Payne AH, Smith AB, Douglas SE, Cooper DG, Stansfield IG, Meeson M, Dodds EE, Jones DN, Wood M, Reavill C, Scorer CA, Worby A, Riley G, Eddershaw P, Ioannou C, Donati D, Hagan JJ, Ratti EA.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):400-5. Epub 2006 Oct 19.

PMID:
17084080
43.

Enantiomerically pure tetrahydroquinoline derivatives as in vivo potent antagonists of the glycine binding site associated to the NMDA receptor.

Di Fabio R, Tranquillini E, Bertani B, Alvaro G, Micheli F, Sabbatini F, Pizzi MD, Pentassuglia G, Pasquarello A, Messeri T, Donati D, Ratti E, Arban R, Dal Forno G, Reggiani A, Barnaby RJ.

Bioorg Med Chem Lett. 2003 Nov 3;13(21):3863-6.

PMID:
14552796
44.

Synthesis and pharmacological characterisation of 2,4-dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists.

Micheli F, Fabio RD, Cavanni P, Rimland JM, Capelli AM, Chiamulera C, Corsi M, Corti C, Donati D, Feriani A, Ferraguti F, Maffeis M, Missio A, Ratti E, Paio A, Pachera R, Quartaroli M, Reggiani A, Sabbatini FM, Trist DG, Ugolini A, Vitulli G.

Bioorg Med Chem. 2003 Jan 17;11(2):171-83.

PMID:
12470711
45.

The selective glycine antagonist gavestinel lacks phencyclidine-like behavioral effects.

Beardsley PM, Ratti E, Balster RL, Willetts J, Trist D.

Behav Pharmacol. 2002 Nov;13(7):583-92.

PMID:
12409996
46.

The continuing evolution of the drug discovery process in the pharmaceutical industry.

Ratti E, Trist D.

Farmaco. 2001 Jan-Feb;56(1-2):13-9.

PMID:
11347954
47.

[Intestinal preparation with an osmotic solution for edema with double contrast media].

Spinetta G, Ratti E.

Radiol Med. 2000 Oct;100(4):240-4. Italian.

PMID:
11155450
48.

Involvement of cholecystokinin within craving for cocaine: role of cholecystokinin receptor ligands.

Crespi F, Corsi M, Reggiani A, Ratti E, Gaviraghi G.

Expert Opin Investig Drugs. 2000 Oct;9(10):2249-58. Review.

PMID:
11060804
49.

Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.

Ursini A, Capelli AM, Carr RA, Cassarà P, Corsi M, Curcuruto O, Curotto G, Dal Cin M, Davalli S, Donati D, Feriani A, Finch H, Finizia G, Gaviraghi G, Marien M, Pentassuglia G, Polinelli S, Ratti E, Reggiani AM, Tarzia G, Tedesco G, Tranquillini ME, Trist DG, Van Amsterdam FT.

J Med Chem. 2000 Oct 5;43(20):3596-613. Erratum in: J Med Chem 2000 Dec 28;43(26):5057. Reggiani A [corrected to Reggiani AM].

PMID:
11020274
50.

Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A.

Quartaroli M, Carignani C, Dal Forno G, Mugnaini M, Ugolini A, Arban R, Bettelini L, Maraia G, Belardetti F, Reggiani A, Trist DG, Ratti E, Di Fabio R, Corsi M.

J Pharmacol Exp Ther. 1999 Jul;290(1):158-69.

PMID:
10381772

Supplemental Content

Support Center